Cu Medical Systems Posts 10.8 Billion Won Operating Profit...Records 22.4% Operating Margin

CU Medical Systems (hereinafter CU Medical) announced on the 26th that on a consolidated basis last year it recorded sales of 48.2 billion won, an 18.6% increase from a year earlier. Over the same period, operating profit came to 10.8 billion won, up 38.6% year-on-year. In particular, the operating margin rose by 3.2 percentage points to 22.4%, and net profit for the year turned positive to 650 million won.

The improvement in earnings was driven by expanded sales in the European market and an improved profit structure. The company has expanded its business scope by maintaining stable trading relationships with existing major customer countries while actively entering new countries, and sales increased on the back of growing demand for the installation of automated external defibrillators (AEDs) across Europe. Based on its local sales network and strategic partnerships, the company expanded supply, and by responding quickly to delivery deadlines, providing easy maintenance, and leveraging its proven quality competitiveness, it increased orders. As a result, the proportion of sales from Europe rose, leading to an overall improvement in profitability.

In particular, the operating margin of 22.4% is about three times higher than the 2024 average of 8.1% for listed medical device companies. The assessment is that the profit structure has been further improved due to increased sales in the European market and cost reductions.

The company previously halted its non-core hospital management support (MSO) business, which it had pursued to expand its scale. Although temporary losses occurred in the process of recognizing related losses and recovering invested capital, the winding down of this business was completed as of 2025, eliminating financial uncertainty. Accordingly, all risks related to non-core businesses have been removed, and stable earnings growth centered on core businesses is expected going forward.

CU Medical has designated this year as the first year of accelerated growth and plans to begin in earnest the launch of its new product "CU-SPX," which enhances convenience by equipping an automated external defibrillator (AED) with a screen, as well as efforts to expand its market share in Japan. Through this, the company intends to continue increasing the proportion of overseas sales.

A company representative said, "This turnaround to profitability is the result of simultaneous sales growth centered on the European market and improvements in our profit structure," adding, "We will further strengthen profitability through a strategy of selection and concentration, and continuously enhance corporate value based on synergies with Bistos, a medical diagnostic device company specializing in biosignal equipment that we acquired at the end of last year."